TY - JOUR
T1 - Serine catabolism generates liver NADPH and supports hepatic lipogenesis
AU - Zhang, Zhaoyue
AU - TeSlaa, Tara
AU - Xu, Xincheng
AU - Zeng, Xianfeng
AU - Yang, Lifeng
AU - Xing, Gang
AU - Tesz, Gregory J.
AU - Clasquin, Michelle F.
AU - Rabinowitz, Joshua D.
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/12
Y1 - 2021/12
N2 - Carbohydrate can be converted into fat by de novo lipogenesis, a process upregulated in fatty liver disease. Chemically, de novo lipogenesis involves polymerization and reduction of acetyl-CoA, using NADPH as the electron donor. The feedstocks used to generate acetyl-CoA and NADPH in lipogenic tissues remain, however, unclear. Here we show using stable isotope tracing in mice that de novo lipogenesis in adipose is supported by glucose and its catabolism via the pentose phosphate pathway to make NADPH. The liver, in contrast, derives acetyl-CoA for lipogenesis from acetate and lactate, and NADPH from folate-mediated serine catabolism. Such NADPH generation involves the cytosolic serine pathway in liver running in the opposite direction to that observed in most tissues and tumours, with NADPH made by the SHMT1–MTHFD1–ALDH1L1 reaction sequence. SHMT inhibition decreases hepatic lipogenesis. Thus, liver folate metabolism is distinctively wired to support cytosolic NADPH production and lipogenesis. More generally, while the same enzymes are involved in fat synthesis in liver and adipose, different substrates are used, opening the door to tissue-specific pharmacological interventions.
AB - Carbohydrate can be converted into fat by de novo lipogenesis, a process upregulated in fatty liver disease. Chemically, de novo lipogenesis involves polymerization and reduction of acetyl-CoA, using NADPH as the electron donor. The feedstocks used to generate acetyl-CoA and NADPH in lipogenic tissues remain, however, unclear. Here we show using stable isotope tracing in mice that de novo lipogenesis in adipose is supported by glucose and its catabolism via the pentose phosphate pathway to make NADPH. The liver, in contrast, derives acetyl-CoA for lipogenesis from acetate and lactate, and NADPH from folate-mediated serine catabolism. Such NADPH generation involves the cytosolic serine pathway in liver running in the opposite direction to that observed in most tissues and tumours, with NADPH made by the SHMT1–MTHFD1–ALDH1L1 reaction sequence. SHMT inhibition decreases hepatic lipogenesis. Thus, liver folate metabolism is distinctively wired to support cytosolic NADPH production and lipogenesis. More generally, while the same enzymes are involved in fat synthesis in liver and adipose, different substrates are used, opening the door to tissue-specific pharmacological interventions.
UR - http://www.scopus.com/inward/record.url?scp=85120074148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120074148&partnerID=8YFLogxK
U2 - 10.1038/s42255-021-00487-4
DO - 10.1038/s42255-021-00487-4
M3 - Article
C2 - 34845393
AN - SCOPUS:85120074148
SN - 2522-5812
VL - 3
SP - 1608
EP - 1620
JO - Nature Metabolism
JF - Nature Metabolism
IS - 12
ER -